2. Academic Validation
  3. Ganoderma microsporum immunomodulatory protein combined with KRASG12C inhibitor impedes intracellular AKT/ERK network to suppress lung cancer cells with KRAS mutation

Ganoderma microsporum immunomodulatory protein combined with KRASG12C inhibitor impedes intracellular AKT/ERK network to suppress lung cancer cells with KRAS mutation

  • Int J Biol Macromol. 2024 Jan 9;259(Pt 2):129291. doi: 10.1016/j.ijbiomac.2024.129291.
Wei-Jyun Hua 1,  Wei-Lun Hwang 2,  Hsin Yeh 3,  Zhi-Hu Lin 3,  Wei-Hung Hsu 4,  Tung-Yi Lin 5
Affiliations

Affiliations

  • 1 Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan; Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • 2 Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • 3 Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • 4 Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; LO-Sheng Hospital Ministry of Health and Welfare, Taipei, Taiwan; School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
  • 5 Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan; Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Biomedical Industry Ph.D. Program, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: [email protected].
PMID: 38211909 DOI: 10.1016/j.ijbiomac.2024.129291
Abstract

KRAS mutations are tightly associated with lung Cancer progression. Despite the unprecedented clinical success of KRASG12C inhibitors, recurrent mechanisms of resistance and other KRAS mutations require further therapeutic approaches. GMI, a protein from the medicinal mushroom Ganoderma microsporum, possesses antitumor activity; whereas, the biological function of GMI on regulating KRAS mutant lung Cancer cells remains unknown. Herein, RNA-sequencing and bioinformatics showed that GMI may regulate KRAS-modulated MAPK and PI3K-AKT pathways in A549 (KRASG12S) cells. Further experiments demonstrated that GMI inhibited KRAS activation and suppressed ERK1/2 and Akt signaling in A549 cells. Intriguingly, GMI inhibited Akt signaling but increased phosphorylation of ERK in H358 (KRASG12C) cells. GMI significantly suppressed tumor growth in LLC1 cells-allograft and H358 cells-xenograft mice. GMI showed a synergistic effect with KRASG12C inhibitors in inhibiting cell growth, KRAS activation and KRAS-mediated downstream signaling, leading to Apoptosis in H358 cells. Combination of GMI and KRASG12C inhibitor, AMG 510, resulted in more durable inhibition of tumor growth and KRAS activity in H358 cells-xenograft mice. This study highlights the potential of GMI, a dietary Fungal protein, as a viable therapeutic avenue for KRAS-mutant lung Cancer in combination with KRASG12C inhibitors.

Keywords

Combination strategies; GMI; Ganoderma microsporum immunomodulatory protein; KRAS mutation; KRAS(G12C) inhibitors.

Figures
Products